A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
A phase 3 trial of Teclistamab, Pomalidomide, Bortezomib in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT05572515 by Janssen Research & Development, LLC, with 614 participants enrolled, started 2023-03-29 and due to reach its primary completion in 2025-10-13. Interventions recorded: Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Teclistamab, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study of Daratumumab
Shares Carfilzomib, Pomalidomide, Dexamethasone, Johnson & Johnson.
- PersonSundar Jagannath
Shares Carfilzomib, Teclistamab, Bortezomib, Multiple myeloma.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.